ArticleJournal of hematology & oncology2020

First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer.

Xingsheng Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.